Unresectable hepatocellular carcinoma (HCC)
Conditions
Interventions
Experimental group:TACE-LVD "dual conversion" therapy
Control group:TACE alone "single conversion" therapy
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion Criteria To accurately evaluate the value of the "dual conversion" strategy, the core cause of initial unresectability is clearly defined as insufficient future liver remnant (FLR). (1).Age 18–75 years; (2).Clinically diagnosed with HCC by pathology or imaging diagnostic criteria; (3).Key criterion: Confirmed by MDT evaluation as unresectable for radical resection due to insufficient FLR (e.g., FLR/standard liver volume < 40% in patients without cirrhosis, < 50% in patients with cirrhosis); the tumor is technically resectable (no unresectable extrahepatic metastasis or major vascular invasion beyond standard criteria). (4).Child-Pugh Class A or B (score <= 7); (5).ECOG performance status 0–1; (6).Signed informed consent.
Exclusion criteria
Exclusion criteria: 2. Exclusion Criteria (1).Definite extrahepatic metastasis or main portal vein tumor thrombus (Vp4); (2).Severe cardiac, pulmonary, or renal insufficiency, unable to tolerate interventional procedures or major hepatectomy; (3).Uncorrectable coagulation dysfunction; (4).Hypersensitivity to lipiodol, contrast media, or related agents; (5).Pregnant or lactating women; (6).Concurrent participation in other interventional clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful conversion resection; | — |
Secondary
| Measure | Time frame |
|---|---|
| FLR hypertrophy evaluation;Survival outcome evaluation;Safety evaluation; | — |
Countries
China
Contacts
Public ContactChang Liu
West China Hospital of Sichuan University
Outcome results
None listed